Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 260
- Registration Number
- NCT05436418
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸City of Hope, Duarte, California, United States
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 20
- Registration Number
- NCT05426252
- Locations
- 🇨🇦
Yogi Chopra, Toronto, Ontario, Canada
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Vascular Therapies, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT05425056
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸The Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Lundquist Institute for Biomedical Innovation, Torrance, California, United States
Short Term Sirolimus Treatment and MRI of the Brain
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 105
- Registration Number
- NCT05386914
- Locations
- 🇺🇸
University of Missouri-Columbia, Columbia, Missouri, United States
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05384756
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 90
- Registration Number
- NCT05357482
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Sirolimus in Graves' Orbitopathy
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 30
- Registration Number
- NCT05345119
- Locations
- 🇮🇹
Endocrinologia II, Pisa, PI, Italy
Daily Topical Rapamycin for Vitiligo
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT05342519
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 430
- Registration Number
- NCT05327023
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05324384
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.